David V. Erbe
Alnylam Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Amyloidosis: Diagnosis, Treatment, Outcomes, Kidney Stones and Urolithiasis Treatments, Adipose Tissue and Metabolism, Peroxisome Proliferator-Activated Receptors, Protein Tyrosine Phosphatases
Most-Cited Works
- → Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses(2001)478 cited
- → An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria(2016)199 cited
- → Structure-Based Optimization of Protein Tyrosine Phosphatase 1B Inhibitors: From the Active Site to the Second Phosphotyrosine Binding Site(2007)157 cited
- → Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent(2008)148 cited
- → Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists(2006)136 cited
- → Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface(2013)112 cited
- → Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis(2020)98 cited
- → Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms(2004)82 cited
- → Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1(2021)78 cited
- → A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia(2011)71 cited